# Vinorelbine Plus Paclitaxel in Treating Patients With Metastatic Prostate Cancer That Is Refractory to Hormone Therapy

> **NCT00003622** · PHASE2 · WITHDRAWN · sponsor: **James Ahlgren**

## Conditions studied

- Prostate Cancer

## Interventions

- **DRUG:** paclitaxel
- **DRUG:** vinorelbine tartrate

## Key facts

- **NCT ID:** NCT00003622
- **Lead sponsor:** James Ahlgren
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 1999-01
- **Primary completion:** 2008-05
- **Final completion:** 2017-02-22
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** No recruitment
- **Last updated:** 2017-07-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00003622

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00003622, "Vinorelbine Plus Paclitaxel in Treating Patients With Metastatic Prostate Cancer That Is Refractory to Hormone Therapy". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00003622. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*